Biofrontera Inc. (BFRI) Stock

Biofrontera Inc. (BFRI) is a Healthcare stock trading at $1.48 (as of 2026-08-21), with a market capitalization of $21.91M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Biofrontera Inc. is a biopharmaceutical company focused on commercializing prescription pharmaceutical products for dermatological conditions in the United States. Its offerings include Ameluz (used with a related medical device), RhodoLED lamps for photodynamic therapy for actinic keratosis, and Xepi for impetigo treatment.

Understand Biofrontera Inc.: how it makes money

Biofrontera commercializes prescription dermatology products in the United States, selling Ameluz (used in combination with a licensor medical device), its RhodoLED lamp series for photodynamic therapy, and Xepi (impetigo cream).

Profit depends on selling a connected dermatology treatment workflow, where Ameluz is used with a licensor medical device and RhodoLED supports the photodynamic therapy treatment process.

Business quality (Weak): Focused product set and clear treatment positioning in dermatology, but the provided data does not include reportable segment revenue or operating KPIs to track day to day drivers.

Bull case

  • Dermatology-focused commercial portfolio: The company commercializes prescription treatments for dermatological conditions, including Ameluz for actinic keratosis (with photodynamic therapy) and Xepi for impetigo.
  • Treatment approach includes both drug and therapy equipment: Biofrontera offers RhodoLED lamp series alongside its prescription drug Ameluz, aligning its offerings with photodynamic therapy delivery.

Bear case

  • Dependence on a licensor for Ameluz combination use: Ameluz is approved for use in combination with the company licensor medical device, which creates reliance on another party's device in the treatment regimen.
  • Unprofitable on operating basis in the latest period provided: For the period ended 2026-03-31, the operating margin was minus 42.8%.
Valuation — source: SEC EDGAR (first-party)
Price$1.48
Market Cap$21.91M
Price / Book3.68
Price / Sales0.47
FCF Yield-36.2%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$41.70M
Net Margin-25.3%
Revenue Growth (YoY)32.9%
EPS Growth (YoY)-91.2%
FCF Growth (YoY)-45.6%
Financial Health — source: SEC EDGAR
Altman Z-Score-5.29 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderRosalind Advisors, Inc. ($941645.00)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOHermann Luebbert
Employees92
CountryUS
IPO Date2021-10-29

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Marker Therapeutics, Inc. (MRKR)
  • Cocrystal Pharma, Inc. (COCP)
  • Neuphoria Therapeutics Inc. (NEUP)
  • Celularity Inc. (CELU)
  • Cyclerion Therapeutics, Inc. (CYCN)
  • Tvardi Therapeutics, Inc. (TVRD)
  • Tempest Therapeutics, Inc. (TPST)
  • KALA BIO, Inc. (KALA)
BFRI earnings history · BFRI institutional & insider holders · BFRI KPIs & operating metrics · BFRI financials · BFRI investor presentations & press releases · BFRI SEC filings · BFRI peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.